Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer study findings have been reported from Celera Inc.
April 23rd, 2009
"Knowledge of estrogen receptor (ER) and progesterone receptor (PR) status has been critical in the evolution of modern targeted therapy of breast cancer and remains essential for making informed therapeutic decisions. Recently, growth factor receptor HER2/neu (ERBB2) status has made it possible to provide another form of targeted therapy linked to the overexpression of this protein," researchers in the United States report. "Presently, pathologists determine the receptor status in formalin-fixed, paraffin-embedded sections using subjective, semi-quantitative immunobistochemistry (IHC) assays and quantitative fluorescence in situ hybridization for HER2. We developed a...
Source: Women's Health Weekly (2009-04-23)
|
